Status | Study |
RECRUITING |
Study Name: Extracorporeal Photopheresis in Sezary Syndrome Condition: Sezary Syndrome Date: 2021-11-16 Interventions: Extracorporeal photopheresis is a process that exposes a collection of white blood cells and plasma to a light sensitizing agent, methoxsalen, and ret |
Not yet recruiting |
Study Name: Pembrolizumab and Interferon Gamma-1b in Treating Patients With Stage IB-IVB Relapsed or Refractory Mycosis Fungoides and Sezary Syndrome Condition: Recurrent Mycosis Fungoides and Sezary Syndrome Refractory Myco Date: 2017-02-22 Interventions: Biological: Interferon Gamma-1b |
Recruiting |
Study Name: Resminostat for Maintenance Treatment of Patients With Advanced Stage Mycosis Fungoides (MF) or Sézary Syndrome (SS) Condition: Mycosis Fungoides Sezary Syndrome Date: 2016-10-26 Interventions: Drug: resminostat Other Name: |
Recruiting |
Study Name: ID Of Prognostic Factors In Mycosis Fungoides/Sezary Syndrome Condition: Mycosis Fungoides Non-Hodgkin's Lymphoma Date: 2016-07-25 |
Completed |
Study Name: VircapSeq Virus Detection in Sézary Syndrome Condition: Lymphoma, T-Cell, Cutaneous Sézary Syndrome Date: 2016-07-15 |
Recruiting |
Study Name: Tissue Repository: CTCL Collection Protocol Condition: Lymphoma, T-Cell, Cutaneous Lymphomatoid Papulosis Date: 2016-07-15 |
Recruiting |
Study Name: TSEB and Brentuximab for Treatment of Mycosis Fungoides & Sezary Syndrome Condition: Mycosis Fungoides Sézary Syndrome Date: 2016-06-30 Interventions: Radiation: TSEB Therapy TSEB i |
Active, not recruiting |
Study Name: Pembrolizumab in Treating Patients With Relapsed or Refractory Stage IB-IVB Mycosis Fungoides or Sezary Syndrome Condition: Recurrent Mycosis Fungoides and Sezary Syndrome Stage IB Mycosi Date: 2014-09-16 Interventions: Other: Laboratory Biomarker Analysis |
Terminated |
Study Name: Effect of Neurokinin-1 Receptor (NK1R) Antagonism on Pruritus in Patients With Sezary Syndrome Condition: Sezary Syndrome Pruritus Date: 2012-06-19 Interventions: Drug: Aprepitant Aprepitant wi |
Completed |
Study Name: Brentuximab Vedotin (SGN-35) in Patients With Mycosis Fungoides With Variable CD30 Expression Level Condition: Non-Hodgkin Lymphoma (NHL) Cutaneous Lymphoma Cutaneous T- Date: 2011-07-14 Interventions: Drug: Brentuximab vedotin 1.8 mg/kg by IV every 3 weeks fo |